Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Monopar Therapeutics Inc.NASDAQ: MNPR
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$52.41M, compared with -$39.71M a year earlier.
Context
- Net debt amounted to 38.0% of total assets at the end of Q1 FY2026, down 34.1 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -32.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (61.68M) USD
- Year-over-year change
- -34.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (61.68M) | -34.6% |
| FY2024 | 2024-12-31 | (45.82M) | -530.6% |
| FY2023 | 2023-12-31 | (7.27M) | +11.1% |
| FY2022 | 2022-12-31 | (8.18M) | +59.7% |
| FY2021 | 2021-12-31 | (20.3M) | — |
Net Debt vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -32.0% is the 9th highest of 11, against a peer median of +27.6%.
- Net debt amounts to 38.0% of total assets for MNPR, versus a peer median of 30.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $562.25M USD | +1324.1% | — | 47.8% | |
| Jun 2026 | $20.55M USD | -12.5% | +186.4% | 2.8% | |
| Dec 2025 | -€5.52M EUR | +84.4% | — | 8.8% | |
| Mar 2026 | -$27.07M USD | -154.3% | — | 15.2% | |
| Mar 2026 | -$30.01M USD | +72.2% | — | 13.8% | |
| Jun 2026 | -$35.13M USD | +40.1% | — | 87.5% | |
| Mar 2026 | -$45.38M USD | -30.9% | — | 22.1% | |
| Mar 2026 | -$52.41M USD | -32.0% | — | 38.0% | |
| Mar 2026 | -$114.34M USD | -144.8% | — | 39.2% | |
| Sep 2026 | -$202.58M USD | +24.6% | — | 40.1% | |
| Mar 2026 | -$544.14M USD | +30.6% | — | 83.4% | |
| Peer median (excluding MNPR) | — | +27.6% | +186.4% | 30.7% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.